With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In colon cancer, the second most common cause of cancer death, such mutations ...

Efficacy of plogosertib (CYC149462), a novel orally bioavailable PLK1 inhibitor, on patient-derived models of colorectal cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal ...

- Company will hold a conference call today at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (CRDF), a clinical-stage biotechnology company leveraging ...

Cardiff Oncology completed patient enrollment in the Phase 2 CRDF-004 trial for RAS-mutated mCRC, with data expected in 2025. Cardiff Oncology, Inc. announced the completion of patient enrollment in ...

Benefits of GLP-1 RAs were consistent across age groups and BMI categories, with semaglutide showing significant efficacy. These results were presented during the press briefing ahead of the 2026 ...